Skip to main content
    A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.15
    -1.11 (-3.93%)

    Market Cap: $3.57B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcutis Biotherapeutics Inc (ARQT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Arcutis Biotherapeutics reported revenue of $376.07M for the fiscal year ended Dec 31, 2025, up 91.3% from the year before. That year, net income was -$16.14M with a net margin of -4.3%, operating cash flow was -$5.63M and free cash flow was -$6.31M. The quarter ended Sep 30, 2026 had revenue of $143.92M and net income of $8.80M.

    Revenue and Margins

    The operating margin was -3.3% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$376.07M+91.3%90.2%-3.3%-4.3%
    Dec 2024$196.54M+229.7%90.3%-65.3%-71.3%
    Dec 2023$59.61M+1517.1%91.6%-404.5%-439.8%
    Dec 2022$3.69MN/A79.5%-8183.0%-8449.8%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 18.8% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$376.07M$196.54M$59.61M$3.69M$0$0$0$0$0
    Cost of revenue$36.70M$19.13M$4.99M$754.00K$0$0$0$0N/A
    Gross profit$339.38M$177.41M$54.62M$2.93M$0$0$0$0N/A
    Research and development$77.05M$76.42M$110.58M$182.44M$145.56M$115.31M$36.52M$17.94M$3.41M
    Operating income-$12.23M-$128.40M-$241.10M-$301.63M-$206.53M-$136.65M-$43.13M-$19.73M-$4.11M
    Net income-$16.14M-$140.04M-$262.14M-$311.46M-$206.36M-$135.68M-$42.00M-$19.25M-$4.98M
    EBITDA-$9.21MN/AN/A-$297.13M-$202.45M-$135.48M-$42.28M-$19.27M-$4.11M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$143.92M$129.86M$105.40M$129.50M$99.22M$81.50M$65.85M$71.36M$44.76M$30.86M$49.57M$13.53M
    Gross profit$131.46M$118.92M$95.61M$117.81M$90.53M$74.01M$57.02M$64.45M$39.25M$27.39M$46.31M$11.28M
    Operating income$9.44M$16.43M-$9.09M$18.39M$8.53M-$14.61M-$24.53M-$7.63M-$39.07M-$50.08M-$31.62M-$61.17M
    Net income$8.80M$15.01M-$11.29M$17.39M$7.41M-$15.89M-$25.06M-$10.79M-$41.54M-$52.33M-$35.38M-$66.28M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $108.96M exceeded cash and equivalents by $66.05M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$432.97M$348.89M$341.37M$449.27M$408.15M$298.27M$107.01M$51.10M$3.82M
    Current assets$411.23M$335.82M$330.43M$437.41M$402.77M$292.83M$106.47M$51.10M$3.82M
    Cash and equivalents$42.91M$71.33M$88.40M$53.64M$96.45M$65.08M$63.34M$39.39M$3.42M
    Total liabilities$243.49M$191.35M$252.70M$239.69M$110.47M$27.65M$5.55M$75.08M$8.81M
    Short-term debt$1.00M$0$735.00K$1.31M$433.00KN/A$178.00KN/AN/A
    Long-term debt$107.96M$107.20M$201.80M$197.77M$72.35MN/AN/AN/A$966.00K
    Shareholder equity$189.48M$157.54M$88.67M$209.58M$297.68M$270.62M-$65.03M-$23.99M-$4.99M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$524.43M$488.54M$460.00M$432.97M$370.98M$352.43M$344.11M$348.89M$437.35M$444.76M$478.54M$341.37M
    Total liabilities$280.46M$267.96M$270.36M$243.49M$212.90M$213.46M$201.45M$191.35M$280.71M$258.33M$253.60M$252.70M
    Cash and equivalents$33.37M$34.12M$34.76M$42.91M$47.12M$72.74M$53.10M$71.33M$134.85M$84.27M$190.10M$88.40M
    Shareholder equity$243.97M$220.58M$189.65M$189.48M$158.07M$138.97M$142.66M$157.54M$156.64M$186.43M$224.94M$88.67M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$5.63M-$112.16M-$247.06M-$257.71M-$174.63M-$113.03M-$42.84M-$14.09M-$3.77M
    Capital expenditures$686.00K$143.00K$428.00K$333.00K$995.00K$321.00K$295.00K$0$295.00K
    Free cash flow-$6.31M-$112.30M-$247.49M-$258.05M-$175.62M-$113.35M-$43.13M-$14.09M-$4.07M
    Dividends paidN/AN/AN/A$122.81M$72.35MN/AN/AN/AN/A
    Investing cash flow-$30.25M$28.82M$180.23M-$87.20M-$75.95M-$181.82M-$26.32M-$11.53M-$11.53M
    Financing cash flow$6.97M$66.20M$101.32M$301.80M$281.95M$298.14M$93.10M$61.59M$7.12M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$18.90M$12.64M$2.24M$26.18M-$1.75M$324.00K-$30.38M-$748.00K-$34.69M-$45.12M-$31.60M-$56.24M
    Capital expenditures$97.00K$158.00K$0$0$0$78.00K$608.00K$5.00M$143.00K$0$0$6.00K
    Free cash flow$18.80M$12.48M$2.24M$26.18M-$1.75M$246.00K-$30.99M-$5.75M-$34.83M-$45.12M-$31.60M-$56.25M
    Last 12 quarters

    Frequently Asked Questions About ARQT

    What is Arcutis Biotherapeutics' annual revenue?

    Arcutis Biotherapeutics reported revenue of $376.07M for the fiscal year ended Dec 31, 2025.

    How fast is Arcutis Biotherapeutics' revenue growing?

    Revenue was up 91.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 367.3%.

    Is Arcutis Biotherapeutics profitable?

    No. Arcutis Biotherapeutics reported net income of -$16.14M for the fiscal year ended Dec 31, 2025, with a net margin of -4.3%.

    How much free cash flow does ARQT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.63M minus capital expenditures of $686.00K produced free cash flow of -$6.31M.

    How much debt does Arcutis Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $107.96M, short-term debt of $1.00M and cash and equivalents of $42.91M.